Login
$NTLA
$9.97 +$0.11 (1.11%) After hours

$NTLA SEC Filings

Filed On Filing
13 Nov 2026 8-K/A: Regulation FD Disclosure

Readying Lonvo-z for Patients with HAE November 12, 2026 Exhibit 99.1

12 Nov 2026 8-K: Results of Operations and Financial Condition

Readying Lonvo-z for Patients with HAE November 12, 2026 Exhibit 99.1

10 Nov 2026 SCHEDULE 13G
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date

03 Nov 2026 Form 4: Leonard John M, Director

Sold 9,000 shares ($108K)

02 Nov 2026 144
28 Oct 2026 Form 4: Marantz Jing L., EVP, Chief Medical Officer

Received 199,822 shares as a grant or award · Granted 275,061 Stock Option (right to buy)

28 Oct 2026 Form 3: Marantz Jing L., EVP, Chief Medical Officer

No securities owned

06 Oct 2026 Form 4: Dube Michael P, VP, Chief Accounting Officer

Sold 1,864 shares ($23.2K)

05 Oct 2026 144
08 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

04 Sep 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

$75 million funded upfront with an additional $325 million tied to milestones, providing

24 Aug 2026 Form 4: Leonard John M, Director

Sold 19,890 shares ($251K) · Sold 2,785 shares ($36.2K)

20 Aug 2026 144
07 Aug 2026 SCHEDULE 13G
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine

24 Jul 2026 Form 4: Dulac Edward J Iii, EVP, Chief Financial Officer

Sold 8,111 shares ($91.2K)

06 Jul 2026 Form 4: Dube Michael P, VP, Chief Accounting Officer

Sold 2,641 shares ($44.3K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support